Où achat cialis sans ordonnance et acheter viagra en France.

Microsoft word - item_6_1_attachment_1_2010draftprohibitedlist_eng_final.doc

AGENDA ITEM # 6.1
ATTACHMENT 1
PROHIBITED LIST
INTERNATIONAL
STANDARD
The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2010
AGENDA ITEM # 6.1
ATTACHMENT 1
THE 2010 PROHIBITED LIST
WORLD ANTI-DOPING CODE
Valid 1 January 2010
All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
(IN- AND OUT-OF-COMPETITION)
PROHIBITED SUBSTANCES
S1. ANABOLIC AGENTS

Anabolic agents are prohibited.
1. Anabolic Androgenic Steroids (AAS)

a. Exogenous* AAS, including:

1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α-
androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone;
boldenone; boldione
(androsta-1,4-diene-3,17-dione); calusterone;
clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole);
dehydrochlormethyltestosterone
(4-chloro-17β-hydroxy-17α-methylandrosta-
1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-
17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol);
fluoxymesterone; formebolone; furazabol
(17β-hydroxy-17α-methyl-5α-
androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-
dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone;
methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);
methandriol; methasterone
(2α, 17α-dimethyl-5α-androstane-3-one-17β-ol);
methyldienolone
(17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1-
testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one);
methylnortestosterone
(17β-hydroxy-17α-methylestr-4-en-3-one);
methyltestosterone; metribolone
(methyltrienolone, 17β-hydroxy-17α-
methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-
norandrostenedione
(estr-4-ene-3,17-dione); norboletone; norclostebol;
norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone;

AGENDA ITEM # 6.1
ATTACHMENT 1

prostanozol (17β-hydroxy-5α-androstano[3,2-c] pyrazole); quinbolone;
stanozolol; stenbolone; 1-testosterone
(17β-hydroxy-5α-androst-1-en-3-
one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one);
trenbolone
and other substances with a similar chemical structure or similar
biological effect(s).

b. Endogenous** AAS when administered exogenously:

androstenediol
(androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-
3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ;
prasterone
(dehydroepiandrosterone, DHEA); testosterone
and the following metabolites and isomers:

5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-
3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol;
androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-
3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol;

4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-
ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; 3α-hydroxy-5α-
androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 19-
norandrosterone; 19-noretiocholanolone.


2. Other Anabolic Agents, including but not limited to:


Clenbuterol, selective androgen receptor modulators (SARMs), tibolone,

zeranol, zilpaterol.

For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the
body naturally.


S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED
SUBSTANCES

The following substances and their releasing factors are prohibited: 1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO),
darbepoetin (dEPO), methoxy polyethylene glycol-epoetin beta
(CERA), hematide];

AGENDA ITEM # 6.1
ATTACHMENT 1
2. Chorionic Gonadotrophin (CG),and Luteinizing Hormone (LH) in
3. Insulins;
4. Corticotrophins;

5. Growth Hormone (GH); Insulin-like Growth Factor-1 (IGF-1),
Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor
(PDGF), Fibroblast Growth Factors (FGFs), Vascular-Endothelial
Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) as well
as any other growth factor affecting muscle, tendon or ligament

protein synthesis/degradation, vascularisation, energy utilization,
regenerative capacity or fibre type switching;

6. Platelet-derived preparations (e.g. Platelet Rich Plasma, “blood
spinning”) administered by intramuscular route. Other routes of
administration require a declaration of Use according to the International
Standard for Therapeutic Use Exemptions.
and other substances with similar chemical structure or similar biological
effect(s).

S3. BETA-2 AGONISTS

All beta-2 agonists (including both optical isomers where relevant) are prohibited except
salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol by inhalation which require a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions. The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol. AGENDA ITEM # 6.1
ATTACHMENT 1

S4. HORMONE ANTAGONISTS AND MODULATORS

The following classes are prohibited:
1. Aromatase inhibitors including, but not limited to: anastrozole, 4-
androstene-3,6,17 trione (6-oxo), androsta-1,4,6-triene-3,17-dione
(androstatrienedione), letrozole, aminoglutethimide, exemestane,
formestane, testolactone.


2. Selective estrogen receptor modulators (SERMs)
including, but not
limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to:
clomiphene, cyclofenil, fulvestrant.

4. Agents modifying myostatin function(s)
including but not limited to:
myostatin inhibitors.

S5. DIURETICS AND OTHER MASKING AGENTS


Masking agents are prohibited. They include:
Diuretics, probenecid, plasma expanders (e.g. glycerol; intravenous
administration of albumin, dextran, hydroxyethyl starch and mannitol) and
other substances with similar biological effect(s).


Diuretics include:
Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone,
etacrynic acid, furosemide, indapamide, metolazone, spironolactone,
thiazides (
e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide),
triamterene
, and other substances with a similar chemical structure or similar
biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and
brinzolamide, which are not prohibited).

A Therapeutic Use Exemption for diuretics and masking agents is not valid if an
Athlete’s urine contains such substance(s) in association with threshold or sub-
threshold levels of an exogenous Prohibited Substance(s).
AGENDA ITEM # 6.1
ATTACHMENT 1
PROHIBITED METHODS

M1. ENHANCEMENT OF OXYGEN TRANSFER

The following are prohibited:

1. Blood doping, including the use of autologous, homologous or heterologous
blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
M2. CHEMICAL AND PHYSICAL MANIPULATION
1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or adulteration (e.g. proteases). 2. Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations.
M3. GENE DOPING
The following, with the potential to enhance athletic performance, are prohibited:
1- The transfer of cells or genetic elements (e.g. DNA, RNA);
2- The use of pharmacological or biological agents that alter gene expression.


Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516)
and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are
prohibited.
AGENDA ITEM # 6.1
ATTACHMENT 1
SUBSTANCES AND METHODS
PROHIBITED IN-COMPETITION
In addition to the categories S1 to S5 and M1 to M3 defined above,
the following categories are prohibited in competition:
PROHIBITED SUBSTANCES
S6. STIMULANTS
All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2010 Monitoring Program*. Stimulants include: a: Non Specified Stimulants:
Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil;
benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex;
cocaine; cropropamide; crotetamide; dimethylamphetamine;
etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine;

fenproporex; furfenorex; mefenorex; mephentermine; mesocarb;
methamphetamine(d
-); p-methylamphetamine;
methylenedioxyamphetamine; methylenedioxymethamphetamine;
methylhexaneamine (dimethylpentylamine); modafinil; norfenfluramine;
phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam

(carphedon); prenylamine; prolintane.
A stimulant not expressly listed in this section is a Specified Substance.
b: Specified Stimulants (examples):
Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate;
fencamfamin; heptaminol; isometheptene; levmetamphetamine;
meclofenoxate; methylephedrine****; methylphenidate; nikethamide;
norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine;
pemoline; pentetrazol; phenpromethamine; propylhexedrine;
pseudoephedrine*****; selegiline; sibutramine; strychnine;

tuaminoheptane and other substances with a similar chemical structure or
AGENDA ITEM # 6.1
ATTACHMENT 1
* The following substances included in the 2010 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration
(e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5
micrograms per milliliter.
**** Each of ephedrine and methylephedrine is prohibited when its
concentration in urine is greater than 10 micrograms per milliliter.
***** Pseudoephedrine is prohibited when its concentration in urine is greater
than 150 micrograms per milliliter.

S7. NARCOTICS

The following narcotics are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its
derivatives, hydromorphone, methadone, morphine, oxycodone,
oxymorphone, pentazocine, pethidine.

S8. CANNABINOIDS

Natural or synthetic Δ9-tetrahydrocannabinol (THC) and THC-like cannabinoids
(e.g. hashish, marijuana, HU-210) are prohibited.

S9. GLUCOCORTICOSTEROIDS


All glucocorticosteroids are prohibited when administered by oral, intravenous,
intramuscular or rectal routes.
In accordance with the International Standard for Therapeutic Use Exemptions, a declaration of Use must be completed by the Athlete for glucocorticosteroids administered by intraarticular, periarticular, peritendinous, epidural, intradermal and inhalation routes, except as noted below. Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not prohibited and neither require a Therapeutic Use Exemption nor a declaration of use. AGENDA ITEM # 6.1
ATTACHMENT 1
SUBSTANCES PROHIBITED IN PARTICULAR

P1. ALCOHOL

Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.  Aeronautic (FAI)
P2. BETA-BLOCKERS
Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports.
Beta-blockers include, but are not limited to, the following:
Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol,
carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol,
metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

Source: http://www.theuiaa.org/upload_area/files/1/Item_6_1_Attachment_1_2010DraftProhibitedList_ENG_FINAL%20(2)(1).pdf

Slide

Pain Testing Models TetraQ offers a range of techniques for investigating the effectiveness of potential pain drugs, with a focus on in vivo models. We are leaders in in vivo pain models and are continually expanding our offering to include new models. Cisplatin-induced Neuropathy in Rats Vehicle (n=5) Nociceptive Pain (validated) Gabapentin (50 mg/kg) (n=6) Gaba

Microsoft word - raineycv2010.doc

P.O. Box 173460 • Montana State University • Bozeman, MT 59717 (406) 994-2670 • meredith.rainey@msu.montana.edu ____________________________________________________________________________________________________________ EDUCATION Dissertation: Evaluating alternative approaches to identifying wildlife corridors M.A. Biology: Ecology & Evolutionary Biology University of Califor

Copyright © 2010-2014 Pdf Medic Finder